Literature DB >> 30880228

Fifty shades of graft: How to improve the efficacy of faecal microbiota transplantation for decolonization of antibiotic-resistant bacteria.

Benjamin Davido1, Rui Batista2, Aurélien Dinh3, Pierre de Truchis3, E M Terveer4, Bruce Roberts5, Ed J Kuijper4, Silvia Caballero5.   

Abstract

BACKGROUND: Spontaneous decolonization of antibiotic-resistant bacteria (ARB) takes time: approximately 25% after 30 days for carbapenem-producing Enterobacteriaceae or extended-spectrum beta-lactamase-producing Enterobacteriaceae. Faecal microbiota transplantation (FMT) has been proposed as a new strategy to promote decolonization in order to reduce the risk of superinfection due to these ARB. This paper discusses the literature on the use of FMT for this indication, and the improvement levers available to promote its efficacy.
METHODS: Literature available to date concerning the use of FMT to eradicate ARB was reviewed, and the different factors that may have influenced the efficacy of decolonization were evaluated.
RESULTS: Four axes that could have played major roles in the efficacy of FMT were identified: bowel preparation before FMT; donor; dose; and thermal conditioning of faeces. The positive or negative impact of each on the outcome of FMT is discussed.
CONCLUSION: Although FMT is very efficient for the eradication of Clostridium difficile, the same 'recipe' cannot be used for the eradication of ARB. Working together with expert centres may help to improve the efficacy of FMT for this indication, and enable the reduction of in-hospital isolation precautions.
Copyright © 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Antibiotic; Antibiotic-resistant bacteria; Efficacy; Faecal; Faecal microbiota transplantation; Resistance

Mesh:

Year:  2019        PMID: 30880228     DOI: 10.1016/j.ijantimicag.2019.03.008

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  7 in total

1.  Microbiome-pathogen interactions drive epidemiological dynamics of antibiotic resistance: A modeling study applied to nosocomial pathogen control.

Authors:  Laura Temime; Lulla Opatowski; David Rm Smith
Journal:  Elife       Date:  2021-09-14       Impact factor: 8.140

Review 2.  Fecal microbiota transplantation in the treatment of intestinal steroid-resistant graft-versus-host disease: two case reports and a review of the literature.

Authors:  Monika Maria Biernat; Donata Urbaniak-Kujda; Jarosław Dybko; Katarzyna Kapelko-Słowik; Iwona Prajs; Tomasz Wróbel
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

3.  Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic Resistant Organisms (FERARO): a prospective, randomised placebo-controlled feasibility trial.

Authors:  Blair Merrick; Emily Robinson; Catey Bunce; Liz Allen; Karen Bisnauthsing; Chi Chi Izundu; Jordana Bell; Gregory Amos; Manu Shankar-Hari; Anna Goodman; Debbie L Shawcross; Simon D Goldenberg
Journal:  BMJ Open       Date:  2020-05-25       Impact factor: 2.692

4.  Randomised, double-blind, placebo-controlled, phase 2, superiority trial to demonstrate the effectiveness of faecal microbiota transplantation for selective intestinal decolonisation of patients colonised by carbapenemase-producing Klebsiella pneumoniae (KAPEDIS).

Authors:  Elena Pérez-Nadales; Ángela Cano; Manuel Recio; María José Artacho; Julia Guzmán-Puche; Antonio Doblas; Elisa Vidal; Clara Natera; Luis Martínez-Martínez; Julian Torre-Cisneros; Juan José Castón
Journal:  BMJ Open       Date:  2022-04-06       Impact factor: 2.692

Review 5.  Impacts of Gut Microbiota on the Immune System and Fecal Microbiota Transplantation as a Re-Emerging Therapy for Autoimmune Diseases.

Authors:  Ashenafi Feyisa Beyi; Michael Wannemuehler; Paul J Plummer
Journal:  Antibiotics (Basel)       Date:  2022-08-12

6.  Investigation and Analysis of the Colonization and Prevalence of Carbapenem-Resistant Enterobacteriaceae in Pediatric Liver Transplant Recipients.

Authors:  Yan Sun; Lixin Yu; Wei Gao; Jinzhen Cai; Wentao Jiang; Wei Lu; Yihe Liu; Hong Zheng
Journal:  Infect Drug Resist       Date:  2021-05-25       Impact factor: 4.003

7.  Proof-of-concept trial of the combination of lactitol with Bifidobacterium bifidum and Lactobacillus acidophilus for the eradication of intestinal OXA-48-producing Enterobacteriaceae.

Authors:  Juan Carlos Ramos-Ramos; Fernando Lázaro-Perona; José Ramón Arribas; Julio García-Rodríguez; Jesús Mingorance; Guillermo Ruiz-Carrascoso; Alberto M Borobia; José Ramón Paño-Pardo; Rafael Herruzo; Francisco Arnalich
Journal:  Gut Pathog       Date:  2020-04-07       Impact factor: 4.181

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.